image
Agios Pharmaceuticals, Inc. AGIO
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 40.0
-0.867 %
$ 2.32 B
Market Cap
3.47
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one AGIO stock under the worst case scenario is HIDDEN Compared to the current market price of 40 USD, Agios Pharmaceuticals, Inc. is HIDDEN

AGIO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one AGIO stock under the base case scenario is HIDDEN Compared to the current market price of 40 USD, Agios Pharmaceuticals, Inc. is HIDDEN

AGIO Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one AGIO stock under the best case scenario is HIDDEN Compared to the current market price of 40 USD, Agios Pharmaceuticals, Inc. is HIDDEN

AGIO Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart AGIO

image
1M 20%
6M 23%
1Y -21%
3Y 105%
5Y -27%
All
$40.0$40.0$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25Jul '25Jul '25
FINANCIALS
36.5 M REVENUE
36.07%
Growth Rates
1Year 36.07%
3Years 0.00%
5Years -20.91%
7Years -2.32%
10Years -5.66%
-426 M OPERATING INCOME
-8.75%
Growth Rates
1Year -8.75%
3Years -4.01%
5Years 0.03%
7Years -4.13%
10Years -22.90%
674 M NET INCOME
291.35%
Growth Rates
1Year 291.35%
3Years 57.27%
5Years 29.47%
7Years 22.51%
10Years 30.74%
-390 M OPERATING CASH FLOW
-31.68%
Growth Rates
1Year -31.68%
3Years 1.45%
5Years -1.02%
7Years -4.56%
10Years -20.71%
363 M INVESTING CASH FLOW
51.70%
Growth Rates
1Year 51.70%
3Years -33.73%
5Years 31.78%
7Years 35.24%
10Years 11.94%
14.4 M FINANCING CASH FLOW
165.82%
Growth Rates
1Year 165.82%
3Years 26.39%
5Years -45.10%
7Years -34.70%
10Years -26.98%
8.73 M REVENUE
-18.68%
Growth Rates
1Year 36.07%
3Years 0.00%
5Years -20.91%
7Years -2.32%
10Years -5.66%
-107 M OPERATING INCOME
14.72%
Growth Rates
1Year -8.75%
3Years -4.01%
5Years 0.03%
7Years -4.13%
10Years -22.90%
-89.3 M NET INCOME
7.49%
Growth Rates
1Year 291.35%
3Years 57.27%
5Years 29.47%
7Years 22.51%
10Years 30.74%
-111 M OPERATING CASH FLOW
16.28%
Growth Rates
1Year -31.68%
3Years 1.45%
5Years -1.02%
7Years -4.56%
10Years -20.71%
113 M INVESTING CASH FLOW
329.03%
Growth Rates
1Year 51.70%
3Years -33.73%
5Years 31.78%
7Years 35.24%
10Years 11.94%
1.62 M FINANCING CASH FLOW
-66.56%
Growth Rates
1Year 165.82%
3Years 26.39%
5Years -45.10%
7Years -34.70%
10Years -26.98%
Balance Sheet Agios Pharmaceuticals, Inc.
image
Current Assets 966 M
Cash & Short-Term Investments 894 M
Receivables 4.11 M
Other Current Assets 67.8 M
Non-Current Assets 698 M
Long-Term Investments 638 M
PP&E 54.6 M
Other Non-Current Assets 4.72 M
53.73 %4.08 %38.38 %3.28 %Total Assets$1.7b
Current Liabilities 81.2 M
Accounts Payable 16.6 M
Short-Term Debt 16.8 M
Other Current Liabilities 47.7 M
Non-Current Liabilities 41.1 M
Long-Term Debt 0
Other Non-Current Liabilities 41.1 M
13.61 %13.73 %39.05 %33.61 %Total Liabilities$122.2m
EFFICIENCY
Earnings Waterfall Agios Pharmaceuticals, Inc.
image
Revenue 36.5 M
Cost Of Revenue 4.16 M
Gross Profit 32.3 M
Operating Expenses 458 M
Operating Income -426 M
Other Expenses -1.1 B
Net Income 674 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)36m(4m)32m(458m)(426m)1b674mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
88.59% GROSS MARGIN
88.59%
Averages
1Year 88.59%
3Years 80.40%
5Years 67.96%
7Years 76.74%
10Years -39.82%
-1166.47% OPERATING MARGIN
-1166.47%
Averages
1Year -1166.47%
3Years -1786.02%
5Years -1102.73%
7Years -894.18%
10Years -749.34%
1845.92% NET MARGIN
1845.92%
Averages
1Year 1845.92%
3Years 3.24%
5Years -31.05%
7Years -122.60%
10Years -207.29%
43.72% ROE
43.72%
Averages
1Year 43.72%
3Years -2.15%
5Years 6.77%
7Years -11.20%
10Years -25.17%
40.51% ROA
40.51%
Averages
1Year 40.51%
3Years -1.03%
5Years 13.85%
7Years -2.23%
10Years -12.69%
-24.99% ROIC
-24.99%
Averages
1Year -24.99%
3Years -26.59%
5Years 0.45%
7Years -14.32%
10Years -22.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Agios Pharmaceuticals, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 674 M
Depreciation & Amortization 5.65 M
Capital Expenditures -1.68 M
Stock-Based Compensation 42.8 M
Change in Working Capital -19.8 M
Others -1.11 B
Free Cash Flow -392 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Agios Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AGIO of $58.5 , with forecasts ranging from a low of $51 to a high of $71 .
AGIO Lowest Price Target Wall Street Target
51 USD 27.50%
AGIO Average Price Target Wall Street Target
58.5 USD 46.25%
AGIO Highest Price Target Wall Street Target
71 USD 77.50%
Price
Max Price Target
Min Price Target
Average Price Target
757570706565606055555050454540403535303025252020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Agios Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
1.11 M USD 5
3-6 MONTHS
1.22 M USD 7
6-9 MONTHS
2.4 M USD 5
9-12 MONTHS
599 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders AMSTERDAM--(BUSINESS WIRE)-- #biotech--Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across th. businesswire.com - 1 month ago
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 Agios Pharmaceuticals, Inc. announced that its management team is scheduled to present at the Goldman Sachs Healthcare Conference on June 9 at 8:40 a.m. ET globenewswire.com - 1 month ago
Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th European Hematology Association (EHA) Congress (EHA 2025) in Milan, Italy, June 12-15, 2025. globenewswire.com - 2 months ago
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 8:00 am ET. globenewswire.com - 2 months ago
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same. zacks.com - 2 months ago
Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 8:00 am PT/11:00 am ET. globenewswire.com - 2 months ago
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call. seekingalpha.com - 2 months ago
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago. zacks.com - 2 months ago
Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights – U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND ® (mitapivat) in Thalassemia,  with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track, with Topline Results Expected in Late 2025; Potential U.S. Commercial Launch in 2026 – – Tebapivat Advancing in Clinical Trials for Lower-Risk Myelodysplastic Syndromes (LR-MDS) and Sickle Cell Disease – – PYRUKYND Net Revenue of $8.7 Million in Q1; Cash, Cash Equivalents and Marketable Securities of $1.4 Billion as of March 31, 2025 – CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today reported business highlights and financial results for the first quarter ended March 31, 2025. globenewswire.com - 2 months ago
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. globenewswire.com - 3 months ago
New Strong Sell Stocks for April 8th AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025. zacks.com - 3 months ago
8. Profile Summary

Agios Pharmaceuticals, Inc. AGIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.32 B
Dividend Yield 0.00%
Description Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Contact 88 Sidney Street, Cambridge, MA, 02139-4169 https://www.agios.com
IPO Date July 24, 2013
Employees 486
Officers Dr. Shin-San Su Ph.D. Co-Founder Ms. Tsveta Milanova Chief Commercial Officer Dr. Craig B. Thompson M.D. Co-Founder Mr. Brian M. Goff M.B.A. Chief Executive Officer & Director Dr. Lewis clayton Cantley Ph.D. Co-Founder Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of Research & Development Mr. T. J. Washburn Vice President, Controller & Principal Accounting Officer Ms. Cecilia Jones Chief Financial Officer Mr. James William Burns Corporate Secretary & Chief Legal Officer Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder